- Home
- CLLS vs VTYX Comparison
CLLS vs VTYX Comparison
Compare CLLS & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- VTYX
- Stock Information
- Founded
- CLLS 1999
- VTYX 2018
- Country
- CLLS France
- VTYX United States
- Employees
- CLLS N/A
- VTYX N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- CLLS Health Care
- VTYX Health Care
- Exchange
- CLLS Nasdaq
- VTYX Nasdaq
- Market Cap
- CLLS 144.4M
- VTYX 154.9M
- IPO Year
- CLLS 2007
- VTYX 2021
- Fundamental
- Price
- CLLS $1.58
- VTYX $1.24
- Analyst Decision
- CLLS Buy
- VTYX Buy
- Analyst Count
- CLLS 3
- VTYX 4
- Target Price
- CLLS $7.00
- VTYX $11.33
- AVG Volume (30 Days)
- CLLS 79.4K
- VTYX 982.1K
- Earning Date
- CLLS 05-27-2025
- VTYX 05-08-2025
- Dividend Yield
- CLLS N/A
- VTYX N/A
- EPS Growth
- CLLS N/A
- VTYX N/A
- EPS
- CLLS N/A
- VTYX N/A
- Revenue
- CLLS $49,217,000.00
- VTYX N/A
- Revenue This Year
- CLLS $48.52
- VTYX N/A
- Revenue Next Year
- CLLS $5.17
- VTYX N/A
- P/E Ratio
- CLLS N/A
- VTYX N/A
- Revenue Growth
- CLLS 435.38
- VTYX N/A
- 52 Week Low
- CLLS $1.10
- VTYX $0.78
- 52 Week High
- CLLS $3.32
- VTYX $5.66
- Technical
- Relative Strength Index (RSI)
- CLLS 60.44
- VTYX 50.66
- Support Level
- CLLS $1.46
- VTYX $1.15
- Resistance Level
- CLLS $1.65
- VTYX $1.48
- Average True Range (ATR)
- CLLS 0.08
- VTYX 0.11
- MACD
- CLLS -0.00
- VTYX 0.01
- Stochastic Oscillator
- CLLS 75.00
- VTYX 44.19
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.